FORA Capital’s Verve Therapeutics VERV Stock Holding History

FORA Capital’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,971	Closed	-$54.7K	–	711
2025 Q1	$54.7K	Buy	+11,971	New	+$80.2K	0.01%	478

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FORA Capital's VERV Position: Q2 2025 in Review

FORA Capital sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 11,971 shares — an estimated $54.7K sold.

FORA Capital first reported a position in VERV in Q1 2025 and held it in 1 quarter. The position peaked at $54.7K in Q1 2025. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

FORA Capital reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
FORA Capital sold 11,971 Verve Therapeutics shares in Q2 2025, an estimated $54.7K.
FORA Capital first reported a position in Verve Therapeutics in Q1 2025 and held it in 1 quarter.
FORA Capital's Verve Therapeutics position peaked at $54.7K in Q1 2025.
175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on FORA Capital's 13F filing for Q2 2025, filed 13 Aug 2025.